Skip to main content

Advertisement

SpringerLink
Log in

Cardiac amyloidosis

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation. Most patients who have symptomatic cardiac involvement do not survive long enough to complete chemotherapy and therefore may not have the opportunity to show treatment benefit. Early diagnosis and treatment before the organ dysfunction has become irreversible are therefore essential to allow adequate duration of therapy. Lifesaving intervention with cardiac transplantation provides a window of opportunity in which other measures can be instituted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Falk RH, Comenzo RL, Skinner M: The systemic amyloidosis. N Engl J Med 1997, 337:898–909. This article is a comprehensive review of different types of amyloidosis as well as their diagnosis, treatment, and prognosis.

    Article  PubMed  CAS  Google Scholar 

  2. Booth DR, Tan SY, Hawkins P, et al.: A novel variant of transthyretin, 59 Thr-Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995, 91:962–967.

    PubMed  CAS  Google Scholar 

  3. Schnitzer TJ, Ansell BM: Amyloidosis in juvenile polyarthritis. Arthritis Rheum 1977, 20:245–252.

    PubMed  CAS  Google Scholar 

  4. David J: Amyloidosis in juvenile chronic arthritis. Clin Exp Rheumatol 1991, 9:73–78.

    PubMed  CAS  Google Scholar 

  5. Merlini G: Treatment of primary amyloidosis. Semin Hematol 1995, 32:60–79. This article describes different treatment options, therapeutic developments, and supportive therapy for amyloidosis.

    PubMed  CAS  Google Scholar 

  6. Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine. N Engl J Med 1997, 336:1202–1207.

    Article  PubMed  CAS  Google Scholar 

  7. Skinner M, Anderson JA, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomised trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996, 100:290–298.

    Article  PubMed  CAS  Google Scholar 

  8. Gertz MA, Kyle RA, Greipp PR, et al.: Response rates and survival in primary systemic amyloidosis. Blood 1991, 77:257–262.

    PubMed  CAS  Google Scholar 

  9. Persey MR, Lovat LB, Apperley JF, et al.: Intensive chemotherapy for amyloidosis. Br J Rheumatol 1996, 35(suppl 1):12.

    Google Scholar 

  10. Cohen AS, Rubinow A, Anderson JJ, et al.: Survival of patients with primary (AL) amyloidosis. Colchicinetreated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987, 82:1182–1190.

    Article  PubMed  CAS  Google Scholar 

  11. Comenzo RL, Vosburgh E, Falk RH, et al.: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662–3670.

    PubMed  CAS  Google Scholar 

  12. Van Buren M, Hene RJ, Verdonck LF, et al.: Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995, 122:508.

    PubMed  Google Scholar 

  13. Moreau P, Milpied N, de Faucal P, et al.: High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996, 87:3063–3064.

    PubMed  CAS  Google Scholar 

  14. Hosenpud JD, DeMarco T, Frazier OH, et al.: Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation: follow-up results of a multicenter survey. Circulation 1991, 84(suppl III):338–343.

    Google Scholar 

  15. Fernandez AL, Herreros JM, Monzonis AM, et al.: Heart transplantation for Finnish type familial systemic amyloidosis. Scand Cardiovasc J 1997, 31:357–359.

    PubMed  CAS  Google Scholar 

  16. Hall R, Hawkins PN: Cardiac transplantation for AL amyloidosis: good quality of life is possible for several years. Br Med J 1994, 309:1135–1137.

    CAS  Google Scholar 

  17. Gertz M, Kyle R: Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993, 44:125–128.

    Article  PubMed  CAS  Google Scholar 

  18. Merlini G, Ascari E, Amboldi N, et al.: Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of fibrillogenesis. Proc Natl Acad Sci U S A 1995, 92:2959–2963.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., 53226, Milwaukee, WI, USA

    Kiran Kashyap MD & Jeffrey D. Hosenpud MD

Authors
  1. Kiran Kashyap MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey D. Hosenpud MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kashyap, K., Hosenpud, J.D. Cardiac amyloidosis. Curr Treat Options Cardio Med 1, 209–217 (1999). https://doi.org/10.1007/s11936-999-0037-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-999-0037-1

Keywords

Search

Navigation